TABLE 1.
Demographic, clinical, and laboratory characteristics of patients with COVID-19.
| Patients, n | 33 |
| Age, years | 63 (22.5) |
| Females, n | 12/33 (36%) |
| Clinical features | |
| Dyspnea | 14/33 (42%) |
| Respiratory failure | 13/33 (39%) |
| Fever | 11/33 (33%) |
| Gastrointestinal | 4/33 (12%) |
| Cough, sneeze | 4/33 (12%) |
| Asthenia | 3/33 (9%) |
| Osteoarticular symptoms | 2/33 (6%) |
| Lipothymia | 1/33 (3%) |
| Severe COVID-19, n | 33/33 (100%) |
| Respiratory support | 33/33 (100%) |
| ICU admission | 2/33 (6%) |
| Death | 2/33 (6%) |
| Respiratory support, n | 33/33 (100%) |
| Oxygen therapy | 33/33 (100%) |
| Nasal cannulas | 33/33 (100%) |
| VentiMask | 29/33 (88%) |
| HFNC | 10/33 (30%) |
| Mechanic support | 19/33 (58%) |
| CPAP | 19/19 (100%) |
| OTI | 1/19 (5%) |
| Concomitant diseases*, n | 6/33 (18%) |
| Cardiac diseases | 5/6 (83%) |
| Acute coronary syndrome | 3/5 (60%) |
| Left ventricular hypertrophy | 1/5 (20%) |
| Chronic coronary artery disease | 1/5 (20%) |
| Extra-cardiac diseases | 1/6 (17%) |
| Diabetes mellitus type II | 1/1 (100%) |
| Chronic kidney disease | 1/1 (100%) |
| QTc prolonging-drugs, n | 24/33 (73%) |
| Pantoprazole | 20/24 (83%) |
| Indapamide | 3/24 (13%) |
| Paroxetine | 3/24 (13%) |
| Furosemide | 2/24 (8%) |
| Dextetomedine | 1/24 (4%) |
| Lansoprazole | 1/24 (4%) |
| Esomeprazole | 1/24 (4%) |
| Tacrolimus | 1/24 (4%) |
| Venlafaxine | 1/24 (4%) |
| Amiodarone | 1/24 (4%) |
| Mean QT-drugs number per patient | 1.0 ± 0.0.8 |
| Mean QTc-prolonging risk factor number per patient** | 1.3 ± 1.0 |
| Patients without QT-prolonging risk factors, n | 8/33 (24%) |
*Diseases recognized to be a risk factor for QTc prolongation (14–20); **including diseases and QTc-prolonging drugs.
COVID-19, Coronavirus disease 2019; HFNC, High flow nasal cannula; CPAP, Continuous positive airway pressure; OTI, Oreotracheal intubation.
Values are expressed as median (interquartile range), frequency count and percentages, or mean (±standard deviation).